Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial

Author(s): Kristal AR, Till C, Platz EA, Song X, King IB, et al.

Abstract

Background:Lycopene has been promoted for prostate cancer prevention, despite the inconsistency of scientific evidence.

Methods:This nested case-control study examined whether serum lycopene was associated with prostate cancer risk among participants in the Prostate Cancer Prevention Trial, a placebo-controlled trial of finasteride for prostate cancer prevention. Presence or absence of cancer was determined by prostate biopsy, recommended during the trial due to elevated prostate specific antigen (PSA) level or abnormal digital rectal examination (DRE) and offered to all men at the trial end. There were 1,683 cases (461 Gleason score ≥ 7, 125 Gleason score ≥ 8) and 1,751 controls.

Results:There were no associations of lycopene with prostate cancer risk. The odds ratios for a linear increase in lycopene (per 10 μg/dL) were 0.99 (95% CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively. In the placebo arm, a 10 μg/dL increase in lycopene was associated with a 7% (95% CI: 14-0) reduced risk of cancer diagnosed following an elevated PSA or abnormal DRE, which are cancers that best match those detected in screened populations. However, a 10 μg/dL increase in lycopene was also associated with an 8% (95% CI: 1-16) increased risk of cancer diagnosed without a biopsy prompt, which are cancers generally not detected. These findings were similar for low- and high-grade cancer.

Conclusion:This study does not support a role for lycopene in prostate cancer prevention.

Impact:Scientists and the public should understand that early studies supporting an association of dietary lycopene with reduced prostate cancer risk have not been replicated in studies using serum biomarkers of lycopene intake. Recommendations of professional societies to the public should be modified to reflect the likelihood that increasing lycopene intake will not affect prostate cancer risk.

Similar Articles

Role of lycopene and tomato products in prostate health

Author(s): Stacewicz-Sapuntzakis M, Bowen PE

Plant extracts: sense or nonsense?CurrOpinUrol 18: 16-20

Author(s): Madersbacher S, Berger I, Ponholzer A, Marszalek M

Lycopene inhibits the growth of normal human prostate epithelial cells in vitro

Author(s): Obermüller-Jevic UC,Olano-Martin E, Corbacho AM, Eiserich JP, van der Vliet A, et al.

Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate

Author(s): Herzog A, Siler U, Spitzer V, Seifert N, Denelavas A, et al.

Lycopene inhibits disease progression in patients with benign prostate hyperplasia

Author(s): Schwarz S,Obermüller-Jevic UC, Hellmis E, Koch W, Jacobi G, et al.

Diet adherence dynamics and physiological responses to a tomato product whole-food intervention in African-American men

Author(s): Park E,Stacewicz-Sapuntzakis M, Sharifi R, Wu Z, Freeman VL, et al.

Lycopene and prostate cancer

Author(s): Barber NJ, Barber J

Tomatoes, lycopene, and prostate cancer: progress and promise

Author(s): Hadley CW, Miller EC, Schwartz SJ, Clinton SK

A food-based formulation provides lycopene with the same bioavailability to humans as that from tomato paste

Author(s): Richelle M,Bortlik K, Liardet S, Hager C, Lambelet P, et al.

A physiological pharmacokinetic model describing the disposition of lycopene in healthy men

Author(s): Diwadkar-Navsariwala V, Novotny JA, Gustin DM, Sosman JA, Rodvold KA, et al.

Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas

Author(s): Canene-Adams K,Lindshield BL, Wang S, Jeffery EH, Clinton SK, et al.

Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice

Author(s): Limpens J,Schröder FH, de Ridder CM, Bolder CA, Wildhagen MF, et al.

Chemoprevention of prostate cancer with lycopene in the TRAMP model

Author(s): Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, et al.

Antioxidants block prostate cancer in lady transgenic mice

Author(s): Venkateswaran V,Fleshner NE, Sugar LM, Klotz LH

Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer

Author(s): Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, et al.

Lycopene effects on rat normal prostate and prostate tumor tissue

Author(s): Siler U, Herzog A, Spitzer V, Seifert N, Denelavas A, et al.

Effects of lycopene on protein expression in human primary prostatic epithelial cells

Author(s): Qiu X, Yuan Y, Vaishnav A, Tessel MA, Nonn L, et al.

Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines

Author(s): Teodoro AJ, Oliveira FL, Martins NB, Maia Gde A, Martucci RB, et al.

A prospective study of lycopene and tomato product intake and risk of prostate cancer

Author(s): Kirsh VA,Mayne ST, Peters U, Chatterjee N, Leitzmann MF, et al.

Lycopene for the prevention of prostate cancer

Author(s): Ilic D, Forbes KM, Hassed C

A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk

Author(s): Bunker CH, McDonald AC, Evans RW, de la Rosa N, Boumosleh JM, et al.

Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis

Author(s): Bowen P, Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, et al.

Serenoarepens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH

Author(s): Morgia G, Russo GI, Voce S, Palmieri F, Gentile M, et al.